SEP 3·SEC EDGARLow
Saint Sean sold $322K of BBNX
Saint Sean (President & CEO) sold 16,867 shares of Beta Bionics, Inc. (BBNX) at $19.11 ($0.32M total) on 2026-09-02.
StockNASDAQ · US · USDHealthcare · Medical Devices
$BBNX
Beta Bionics, Inc.
Price · $BBNXvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $BBNX in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $829K 6 txs
Saint Sean2× · $436K
10b5-1 share of filings17%
Top stories · $BBNXMore →
SEP 3·SEC EDGAR
Feider Stephen sold $128K of BBNX
Feider Stephen (Chief Financial Officer) sold 6,675 shares of Beta Bionics, Inc. (BBNX) at $19.11 ($0.13M total) on 2026-09-02.
SEP 3·SEC EDGAR
Hopman Mark sold $102K of BBNX
Hopman Mark (Chief Commercial Officer) sold 5,327 shares of Beta Bionics, Inc. (BBNX) at $19.11 ($0.10M total) on 2026-09-02.
BBNX sentiment & insider activity
Recent BBNX coverage spans earnings, insider activity and market movers.
In the last 30 days, BBNX insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($829K). The most active reporter was Saint Sean, President & CEO, with 2 filings. 17% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving BBNX
Insider sell may signal reduced confidence, but size is modest relative to holdings.
Minor insider sell may signal slight negative sentiment but size is small relative to float.
Minor dilution of insider confidence; unlikely to move price materially.
Beta Bionics reported Q2 2026 revenue of $32M and gross margin of 59%, up from 54% a year earlier, while posting a wider-than-expected adjusted loss of 53 cents per share. The company reaffirmed full-year 2026 revenue guidance of $131M to $136M and raised gross margin guidance to 58.5% to 59.5%.
Beta Bionics reported Q2 2026 EPS of -$0.53, worse than analysts’ -$0.34, on revenue of $32M, up 38% year over year. Gross margin improved to 59.0%. The company reaffirmed full-year revenue guidance of $131M-$136M and raised gross margin guidance to 58.5%-59.5%. Shares fell 4.18% to $15.14, then rose 2.18% after hours.
alphai scores every news story that mentions BBNX with an AI model for sentiment and relevance, and aggregates insider trades from Beta Bionics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $BBNX
Score
Saint Sean sold $322K of BBNX
Saint Sean (President & CEO) sold 16,867 shares of Beta Bionics, Inc. (BBNX) at $19.11 ($0.32M total) on 2026-09-02.
1 min readFeider Stephen sold $128K of BBNX
Feider Stephen (Chief Financial Officer) sold 6,675 shares of Beta Bionics, Inc. (BBNX) at $19.11 ($0.13M total) on 2026-09-02.
1 min readHopman Mark sold $102K of BBNX
Hopman Mark (Chief Commercial Officer) sold 5,327 shares of Beta Bionics, Inc. (BBNX) at $19.11 ($0.10M total) on 2026-09-02.
1 min readBeta Bionics Q2 2026 slides: revenue hits $32M, margins reach 59% By Investing.com
Beta Bionics reported Q2 2026 revenue of $32M and gross margin of 59%, up from 54% a year earlier, while posting a wider-than-expected adjusted loss of 53 cents per share. The company reaffirmed full-year 2026 revenue guidance of $131M to $136M and raised gross margin guidance to 58.5% to 59.5%.
5 min readEarnings call transcript: Beta Bionics misses Q2 2026 EPS as sales rise 38% By Investing.com
Beta Bionics reported Q2 2026 EPS of -$0.53, worse than analysts’ -$0.34, on revenue of $32M, up 38% year over year. Gross margin improved to 59.0%. The company reaffirmed full-year revenue guidance of $131M-$136M and raised gross margin guidance to 58.5%-59.5%. Shares fell 4.18% to $15.14, then rose 2.18% after hours.
6 min read
Beta Bionics posts Q2 beats on 38% sales growth
Beta Bionics (Nasdaq:BBNX) reported Q2 results that beat consensus. For the quarter ended June 30, 2026, it posted a $23.4M loss (53¢/share) on $32.0M revenue, with sales up about 38% versus a year earlier. DME sales were $20.4M (+9%) and PBP sales $11.6M (+153%). It reaffirmed 2026 revenue guidance of $131M to $136M.
4 min readBeta Bionics (Nasdaq: BBNX) lifts Q2 sales to $32M amid ongoing losses
Beta Bionics (Nasdaq: BBNX) reported Q2 2026 net sales of $32.0M, up from $23.2M a year earlier, driven by its iLet insulin delivery device and single-use consumables. Six-month sales were $59.6M. The company reported a six-month net loss of $45.3M. As of June 30, 2026 it had $44.3M cash and $180.8M in U.S. Treasury investments, and an FDA Warning Letter in January 2026 cited quality system and reporting deficiencies.
4 min readBeta Bionics, Inc. (BBNX): Results of Operations and Financial Condition
Beta Bionics, Inc. (BBNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance IRVINE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, tod
6 min readBeta Bionics (BBNX) sees 6.9% stake reported by Divisadero Street group
Beta Bionics, Inc. disclosed in a Schedule 13G that Divisadero Street Capital Management, LP and William Zolezzi report beneficial ownership of 3,072,985 shares, or 6.9% of the common stock. Divisadero Street Partners, L.P. and its GP report 2,612,985 shares, or 5.9%. The filing shows only shared voting and dispositive power.
2 min read
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
Beta Bionics, Inc. (Nasdaq: BBNX) said it will report second-quarter 2026 financial results after market close on July 29, 2026. Management plans a conference call and webcast the same day at 4:30 pm ET to review performance. The webcast link will be posted on the company’s investor site.
2 min read